Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty

Wilson, Alasdair; Brittenden, Julie; Bachoo, Paul; Ford, Isobel; Nixon, Graeme F.

doi:10.1016/j.jvs.2009.06.017

Cited by 10 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Nonetheless, this antiplatelet association has not proven more efficient than simple ASA in reducing the in vitro activation of extracellular signal-related kinases 1/2 (a marker of smooth muscle cell proliferation of the mean in the second phase after stent implantation). 20 Thus, the ASA/ clopidogrel combination seems useful in the first 30 days to reduce early thrombosis during the procedure (ASA alone used with a superficial femoral stent performed better in preventing early occlusion, and was also beneficial in a simple angioplasty). However, it was not so useful in reducing the appearance of re-stenosis in the long term.…”

Section: Discussionmentioning

confidence: 99%

Antiplatelet Therapy in Endovascular Surgery: The RENDOVASC Study

Matas

González

Montull

2013

Annals of Vascular Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Antiplatelet Therapy in Endovascular Surgery: The RENDOVASC Study

Matas

González

Montull

2013

Annals of Vascular Surgery

View full text Add to dashboard Cite

“…On the contrary, the CYP2C19 ∗ 17 variant is associated with increased antiplatelet therapeutic response and a better clinical outcome [11–13]. Additionally, reports show that clopidogrel can prevent restenosis occurrence, partly due to the fact that inhibition of platelet activity would in turn decrease the release of platelet-derived growth factor (PDGF) [14, 15], which is a potent stimulator of vascular smooth muscle cell (VSMC) proliferation and cell migration [16]. …”

Section: Introductionmentioning

confidence: 99%

CYP2C19⁎2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls

Ruedlinger

Prado

Zambrano

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Clopidogrel is an antiplatelet drug especially used in patients undergoing percutaneous coronary interventions (PCI). Polymorphisms within CYP2C19 can result in important interindividual variations regarding therapeutic efficacy. Therefore, we aimed to evaluate the impact of the CYP2C19⁎2 variant (rs4244285) on in-stent restenosis occurrence in Chilean patients who underwent PCI and received clopidogrel. A total of 77 cases with stenosis >50% in the angioplasty site (62.75 ± 9.8 years, 80.5% males) and 86 controls (65.45 ± 9.8 years, 72.1% males) were studied. The polymorphism was genotyped using TaqMan® Drug Metabolism Genotyping Assays. Overall, CYP2C19⁎2 allele frequency was 8.3%. Diabetes, chronic lesions, and bare metal stents (BMS) were observed more often in cases than in controls (p = 0.05, p = 0.04, and p = 0.02, resp.). Genotypic frequencies did not differ significantly between the groups (p = 0.15). Nonetheless, the mutated allele was observed in a greater proportion in patients without in-stent restenosis (p = 0.055). There was no significant association between the rs4244285 variant and the occurrence of in-stent restenosis after PCI (OR = 0.44; 95% CI: 0.19 to 1.04; p = 0.06). In summary, no association was identified between the CYP2C19⁎2 variant and the development of coronary in-stent restenosis.

show abstract

“…Wilson et al 32 25 Lanas et al 16 17 Yazawa et al 34 14 Ludwig et al 18 18 Zhao et al 36 22 Smith et al 23 20 14 2…”

Section: Effects Of Antiplatelet Medications With Cacl 2 -Dependent Amentioning

confidence: 99%

Effects of Antiplatelet and Nonsteroidal Anti-inflammatory Medications on Platelet-Rich Plasma: A Systematic Review

Frey

Yeh

Jayaram

2020

Orthopaedic Journal of Sports Medicine

View full text Add to dashboard Cite

Background: Platelet-rich plasma (PRP) has wide applications in orthopaedic care. Its beneficial effects are attributed to the growth factor profile from the platelet secretome. In theory, these effects would be diminished by medications that inhibit platelet activation and/or the subsequent release of growth factors. Purpose: To determine whether commonly used antiplatelets, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticoagulant medications affect platelet growth factor release in PRP. Study Design: Systematic review; Level of evidence, 2. Method: A systematic review of the literature related to antiplatelet, anti-inflammatory, and anticoagulant drugs was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We used the Downs and Black objective quality scoring system. The literature search consisted of PubMed and Cochrane Library databases. Search terms consisted of 1 item selected from “platelet-rich plasma,” “platelet-derived growth factor,” and “platelet-rich plasma AND growth factor” combined with 1 item from “antiplatelet,” “aspirin,” “anticoagulant,” and “NSAID.” Only studies published within the past 25 years were included. Results: A total of 15 studies met the inclusion criteria: 7 studies detected no significant decrease in growth factors or mitogenesis, whereas 6 detected a decrease with antiplatelet agents, 1 detected mixed results with an antiplatelet agent, and 1 had mixed results with an antiplatelet agent/vasodilator. In terms of PRP activation, all 3 studies assessing collagen, the 2 studies analyzing adenosine diphosphate alone, and the 1 study investigating arachidonic acid found a decrease in growth factor concentration. Conclusion: Antiplatelet medications may decrease the growth factor release profile in a cyclooxygenase 1– and cyclooxygenase 2–dependent manner. Eight of 15 studies found a decrease in growth factors or mitogenesis. However, more studies are needed to comprehensively understand antiplatelet effects on the PRP secretome.

show abstract

Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty

Cited by 10 publications

References 31 publications

Antiplatelet Therapy in Endovascular Surgery: The RENDOVASC Study

Antiplatelet Therapy in Endovascular Surgery: The RENDOVASC Study

CYP2C19⁎2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls

Effects of Antiplatelet and Nonsteroidal Anti-inflammatory Medications on Platelet-Rich Plasma: A Systematic Review

Contact Info

Product

Resources

About